Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22589301 | 0.84 | RAB9A (0.47) | RAB9ALTA4HNPC1PTPN1NAMPT | |
| SCHEMBL3074382 | 0.83 | PLOD2 (0.53) | LOXL2KMT2APLOD2ALDH1A1POLB | |
| SCHEMBL16060791 | 0.80 | KDM4E (0.48) | RAB9ALOXL2NPC1PTPN1ALDH1A1 | |
| SCHEMBL29091757 | 0.78 | LOXL2 (0.55) | LOXL2NAMPTMEN1KMT2AALDH1A1 | |
| SCHEMBL21935884 | 0.76 | CTNNB1 (0.47) | RAB9ALOXL2NPC1PTPN1KMT2A | |
| SCHEMBL7259829 | 0.76 | RAB9A (0.50) | RAB9ANPC1PTPN1HTR7MEN1 | |
| SCHEMBL2645324 | 0.76 | LTA4H (0.58) | RAB9ALTA4HNPC1PTPN1NAMPT | |
| Hydrochloric Acid SCHEMBL5253545 | 0.75 | LTA4H (0.56) | RAB9ALTA4HNPC1PTPN1NAMPT | |
| SCHEMBL6282620 | 0.74 | GAA (0.57) | RAB9ANAMPTCYP11B1CYP11B2MEN1 | |
| SCHEMBL10906842 | 0.74 | RAB9A (0.65) | RAB9ALTA4HNPC1PTPN1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3181133-B1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER (US) | 2019-07-24 | — | — | EP | disclosed |
| EP-3181133-B1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER (US) | 2019-07-24 | — | — | EP | disclosed |
| EP-3181133-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | Pfizer Inc (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-3181133-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | Pfizer Inc (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2654750-B1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-2654750-B1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-2654750-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | Pfizer Inc (US) | 2013-10-30 | — | — | EP | disclosed |
| US-8536164-B2 | Fused pyridine compounds as casein kinase inhibitors | PFIZER INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536164-B2 | Fused pyridine compounds as casein kinase inhibitors | PFIZER INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536164-B2 | Fused pyridine compounds as casein kinase inhibitors | PFIZER INC. (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2012085721-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085721-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157440-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER INC | 2012-06-21 | — | — | US | disclosed |
| US-20120157440-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER INC | 2012-06-21 | — | — | US | disclosed |
| US-20120157440-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER INC | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157440-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | CSNK1A1, CSNK1A1L, CSNK1E | RAB9A 1987/4885LOXL2 4301/4885LTA4H 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.